Table 3 Hazard ratio of outcomes stratified by the cumulative duration of GLP-1 RAs

Variables

All-cause mortality

n

PY

IR

cHR

(95% CI)

aHR^†

(95% CI)

Non-use of GLP-1 RAs

1093

83691

13.06

1.00

(reference)

1.00

(reference)

Cumulative duration of GLP-1 RAs (days)

 > 182

308

33875

9.09

0.74

(0.65, 0.84)***

0.79

(0.69, 0.90)***

 182–364

101

21978

4.60

0.38

(0.31, 0.46)***

0.44

(0.36, 0.54)***

 > 364

71

28827

2.46

0.17

(0.13, 0.21)***

0.19

(0.15, 0.24)***

P for trend

< 0.0001

Liver-related death

Variables

n

PY

IR

cHR

(95% CI)

aHR^†

(95% CI)

Non-use of GLP-1 RAs

22

83691

0.26

1.00

(reference)

1.00

(reference)

Cumulative duration of GLP-1 RAs (days)

 < 90

3

20886

0.14

0.56

(0.17, 1.88)

0.50

(0.15, 1.69)

 ≧90

4

63794

0.06

0.23

(0.08, 0.68)**

0.25

(0.09, 0.73)*

P for trend

0.0045

Variables

Cardiovascular mortality

n

PY

IR

cHR

(95% CI)

aHR^†

(95% CI)

Non-use of GLP-1 RAs

197

83691

2.35

1.00

(reference)

1.00

(reference)

Cumulative duration of GLP-1 RAs (days)

 > 182

67

33875

1.98

0.90

(0.68, 1.19)

0.97

(0.73, 1.28)

 182–364

24

21978

1.09

0.50

(0.33, 0.76)**

0.59

(0.38, 0.90)*

 > 364

12

28827

0.42

0.16

(0.09, 0.28)***

0.17

(0.09, 0.31)***

P for trend

< 0.0001

Variables

Cardiovascular events

n

PY

IR

cHR

(95% CI)

aHR^†

(95% CI)

Non-GLP-1 RA drug days

1653

80860

20.44

1.00

(reference)

1.00

(reference)

Cumulative duration of GLP-1 RAs (days)

 > 182

710

32784

21.66

1.12

(1.02, 1.22)*

1.16

(1.06, 1.26)**

 182–364

330

21484

15.36

0.77

(0.69, 0.87)***

0.82

(0.73, 0.93)**

 > 364

446

27943

15.96

0.72

(0.65, 0.80)***

0.75

(0.68, 0.83)***

P for trend

0.6991